The Wien Center for Alzheimer’s Disease and Memory Disorders, Mount Sinai Medical Center, Miami Beach will present the:

•  11^th Mild Cognitive Impairment (MCI) Symposium (Saturday, January 19),

•  2^nd Early Alzheimer’s Diagnostic and Treatment Workshop (Sunday morning, January 20), and

•  1^st Mount Sinai of Florida's Early Alzheimer's Public Educational Forum (Sunday afternoon, January 20)

in Miami Beach, Florida, USA.

The symposium's theme will be centered on the progression rates from normal to mild cognitive impairment and then to dementia. 

The MCI Symposium series was initiated in 2003 by the Wien Center for Alzheimer’s Disease and Memory Disorders, at Mount Sinai Medical Center, Miami Beach, under the direction of Ranjan Duara, MD. The purpose of the first and subsequent symposia have been to provide a forum where new information is provided and in-depth discussions can take place about the earliest stages of Alzheimer’s disease and other conditions that result in cognitive impairment in the elderly. The symposia have featured national and international experts in the fields of neurology, neuropsychology, psychiatry, geriatrics, epidemiology, genetics, imaging and neuropathology. The topics discussed at these symposia have included the biology, early detection, prevention and treatment of conditions that result in cognitive impairment in the elderly.

The MCI Symposium and the Early Alzheimer's Diagnostic and Treatment Workshop will attract: Neurologists, Psychiatrists, Geriatricians, Gerontologists, Epidemiologists, Neuropsychologists, Psychologists, Neuroscientists.

The 1^st Mount Sinai of Florida's Early Alzheimer's Public Educational Forum will attract individuals with Alzheimer's disease, at-risk family members and caregivers.

• To educate participants on:

a)   the epidemiological and community studies that have examined demographic, medical, psychological and genetic factors that influence progression rates;

b)   how we measure clinical and biological progression of the disease (using functional and neuropsychological measures, as well as biomarkers) and the different perspectives of disease progression provided by different modalities;

c)   how we assess response to interventions.  

• To provide formal and informal networking opportunities.

• To create a translational and educational segment for the audience-at-large.

Participants who wish to present a poster at the event, may submit an abstract which will be reviewed by the Program Committee. Results of this review will be communicated via email, to each applicant. Please note the conference program will only include the abstracts of registered conference participants - no exceptions will be made.